Acrobat focuses on advancing human health through genomic solutions. The company leverages genomic technologies to develop new approaches in the life sciences sector. Their work aims to provide tools and insights that support health and biological research.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene editing technologies face challenges in achieving the required precision and efficiency for safe and effective therapeutic applications, particularly in addressing complex genetic disorders. The development of curative therapeutics is hindered by off-target effects and limitations in high-throughput screening methods.
Solution
Acrobat Genomics is developing high-throughput genomic solutions that leverage CRISPR technology and machine learning to enhance the precision and efficiency of gene editing. Their approach aims to overcome the limitations of existing methods by improving the accuracy of gene modification and accelerating the discovery of curative therapeutics for genetic disorders. By integrating advanced CRISPR techniques with sophisticated machine learning algorithms, Acrobat Genomics seeks to minimize off-target effects and optimize the delivery of genetic payloads. This technology enables the development of safer and more effective gene-based therapies.
Target Audience
The primary target audience includes researchers, pharmaceutical companies, and clinical organizations involved in the development of gene therapies for genetic disorders.
Features
- High-throughput screening platform for identifying optimal CRISPR guide sequences
- Machine learning algorithms for predicting and minimizing off-target effects
- Enhanced CRISPR delivery methods for increased efficiency and specificity
- Advanced analytics tools for analyzing gene editing outcomes